Therefore, it’s urgently needed to identify factors that can predict a curative effect to define which patients with advanced HCC are most likely to benefit from therapy with anti-PD-1 antibodies in combination with antiangiogenic therapy. Here, PDCD1 is linked to hepatocellular carcinoma.